Tuberculosis surveillance and monitoring in Europe 2019





2017 data

Total population at 23 April 2018 by EUROSTAT: 19 644 350

TB case notifications, 2017

Total number of cases	13 004		
Notification rate per 100 000	66.2		
New ^a and relapses	12 310		
New ^a and relapses notification rate per 100 000	62.7		
Pulmonary	11 0 47	(85.0%)	
of which microscopy-positive	7 255	(65.7%)	
of which laboratory-confirmed	8 878	(80.4%)	
Laboratory-confirmed TB cases	9 194	(70.7%)	
Mean age of new native TB cases	44.0	44.0 years	
Mean age of new foreign TB cases	32.4 years		
Foreign origin of all TB cases	27	(0.2%)	
New (not previously treated)	10 377	(79.8%)	

^a Cases with unknown previous treatment included in new cases.

Drug resistance surveillance and TB/HIV coinfection, 2017

Completeness of DRS data ^a	Yes	
Completeness of HIV datab	Yes	
Case-linked data reporting	Yes	
Cases with DST results	8 183	(89.0%)
Estimated RR-TB among notified pulmonary cases N, (best-low-high)	590-540-650	
Pulmonary MDR-TB cases notified	356	(4.5%)
of which XDR-TB cases	43	(30.3%)
Notified MDR-TB	361	(4.4%)
of which XDR-TB cases	45	(30.8%)
TB cases tested for HIV	10 760	(82.7%)
HIV-positive TB cases	232	(2.2%)
of these on ART	173	(74.6%)


 $[^]a$ National coverage 100% or culturing \ge 90%, C+/all TB cases > 50%, DST done for C+ > 75%, EQA \ge 95%. b More than 50% of TB cases with reported HIV status.

Treatment outcome monitoring


Geographical coverage	Nat	ional		
Outcome cohort	New culture positive pulmonary TB cases notified in 2016 ^a		All MDR-TB cases notified in 2015 ^b	
Case-linked data reporting	Yes			
Cases notified	6 890		537	
Success	5 8 6 1	(85.1%)	222	(41.3%)
Died	512	(7.4%)	94	(17.5%)
Failed	133	(1.9%)	157	(29.2%)
Lost to follow-up	288	(4.2%)	61	(11.4%)
Still on treatment	90	(1.3%)	3	(0.6%)
Not evaluated	6	(0.1%)	0	(0.0%)

^a Treatment outcome as presented is treatment outcome after 12 months. ^b Treatment outcome as presented is treatment outcome after 24 months.


TB notification rates by treatment history, 2008-2017




New and relapsed TB cases - notification rates by age group, 2008-2017




TB cases by geographical origin, 2008-2017




TB/HIV coinfection, 2008-2017



MDR-TB cases by previous treatment history, 2008-2017



Treatment outcome, new culture-confirmed pulmonary TB cases, 2007-2016



Source: European Centre for Disease Prevention and Control/WHO Regional Office for Europe. Tuberculosis surveillance and monitoring in Europe 2019 – 2017 data. Stockholm: ECDC; 2019